DMD and Duchenne muscular dystrophy: In Duchenne muscular dystrophy (DMD), Elevidys received accelerated approval based on micro-dystrophin expression, yet the EMBARK Phase 3 trial did not meet its primary functional endpoint, and secondary outcomes showed only modest, non-significant trends.